Therapeutic Indications

Aglinox is an oral medication primarily indicated for the management of type 2 diabetes mellitus in adults. It is used to improve glycemic control when diet and exercise alone do not provide adequate blood sugar management.

Primary Uses

The medication is utilized in the following clinical scenarios:

• Monotherapy: As a standalone pharmacological treatment for patients who cannot manage blood glucose levels through lifestyle modifications alone.
• Combination Therapy: In conjunction with other antihyperglycemic agents, such as metformin, sulfonylureas, or insulin, when a single medication is insufficient to reach target glucose levels.

Mechanism of Action and Benefits

Aglinox belongs to a class of drugs that helps the pancreas produce more insulin more efficiently and reduces the amount of sugar produced by the liver. The primary clinical benefits associated with its use include:

• Reduction of HbA1c Levels: Consistent use helps lower glycated hemoglobin (HbA1c), which is a key indicator of long-term blood sugar control.
• Postprandial Glucose Management: It assists in regulating blood sugar spikes that occur after meals.
• Fasting Plasma Glucose Control: It contributes to maintaining stable blood sugar levels during periods of fasting, such as overnight.

By maintaining blood glucose levels within a target range, the medication helps reduce the long-term risk of complications associated with persistent hyperglycemia.

Aglinox (Repaglinide) is officially permitted for use only in adults with Type 2 Diabetes Mellitus. Its eligibility profile is strictly defined by regulatory authorities to exclude several specific patient populations.

Contraindicated Populations

The medicine is contraindicated and must not be used by individuals with Type 1 Diabetes Mellitus (T1DM), Diabetic Ketoacidosis, or a severe hepatic function disorder. Use is also strictly prohibited for patients with a known hypersensitivity to Repaglinide or those receiving concomitant treatment with Gemfibrozil.

Restricted and Non-Recommended Use

Use is not recommended in several special populations because safety and efficacy data have not been established. These groups include children and adolescents (under 18 years) and older adults above 75 years of age. Furthermore, Aglinox is not recommended during pregnancy or breastfeeding.

For patients with severe renal impairment, the medicine is allowed under conditional use requiring careful monitoring, while individuals with non-severe impaired hepatic function are also generally not recommended for treatment. These restrictions ensure the medicine is used only in populations where its safety profile is defined by official labeling.

Aglinox, containing Repaglinide, has documented interaction patterns based on its metabolic pathways, as outlined in official regulatory information. The primary constraints involve substances that alter the Repaglinide plasma concentration and blood glucose-lowering effect.

---

Officially Documented Interaction Restrictions

Classification	Interacting Substance/Type	Official Restriction	Interaction Outcome
Contraindicated	Gemfibrozil	Must not be co-administered	Significantly increased Repaglinide exposure, high risk of severe hypoglycemia
Use with Caution	Strong CYP2C8/CYP3A4 Inhibitors	Caution required due to reduced clearance	Increased Repaglinide plasma concentrations
Use with Caution	Strong CYP Inducers (e.g., Rifampicin, St John's wort)	Caution required due to enhanced clearance	Decreased Repaglinide plasma concentrations
Additive Effect	Other Antidiabetic Agents	Risk of additive blood glucose reduction	Enhanced risk of hypoglycemia

---

Pharmacokinetic and Pharmacodynamic Interactions

The most clinically significant interactions are pharmacokinetic, resulting from the inhibition or induction of the hepatic enzymes CYP2C8 and CYP3A4, and the OATP1B1 transporter. Inhibitors like Ciclosporin can increase exposure, while inducers like Rifampicin can cause a substantial decrease. Pharmacodynamic interactions occur with other substances that lower blood glucose, potentially prolonging or enhancing the effect. Furthermore, excessive intake of alcohol is documented as potentially potentiating the risk of severe low blood sugar.

Target: Pancreatic beta-Cell Ion Channel Blockade

Aglinox acts directly on the ATP-sensitive potassium (mathbfKATP) channel in pancreatic beta-cells by binding to its SUR1 subunit and inhibiting the channel's function. This specific molecular interaction is the primary step that prevents potassium ions from exiting the cell, causing the cell membrane to depolarize.

---

️ Cascade: Intracellular Calcium Signaling

The beta-cell depolarization forces the activation and opening of voltage-dependent calcium channels (, VDCCs), leading to a sharp influx of extracellular calcium ions (,mathbfCa^2+). This surge in intracellular Ca^2+ is the essential chemical signal that triggers the beta-cell to release its stored insulin via exocytosis.

---

⬆️ Effect: Glucose-Dependent Secretion

This mechanism is inherently glucose-dependent and relies on functional insulin stores within the beta-cells. The resulting physiological effect is a time-limited increase in circulating insulin, which acts systemically to facilitate glucose uptake by peripheral tissues and suppress glucose production by the liver, resulting in a lowering of the circulating glucose concentration.

Aglinox (repaglinide) is administered via the oral route as a tablet and follows a pattern that is dependent upon meal consumption. The medicine is available in 0.5 mg, 1 mg, and 2 mg tablets.

Dosing and Timing	Official Instruction
Starting Dose	Typically begins at 0.5 mg before each main meal, though 1 mg or 2 mg may be used depending on prior blood sugar control and treatment history.
Frequency	Dosing occurs 2, 3, or 4 times a day, corresponding to the number of main meals consumed.
Meal Timing	The dose must be taken preprandially, generally within 15 minutes of starting the meal, and should not be taken more than 30 minutes before eating.
Maintenance	The maintenance range is 0.5 mg to 4 mg per dose, with a maximum single dose of 4 mg and an absolute maximum total daily dose of 16 mg.

Procedural Constraints and Adjustments

Dose titration must be performed incrementally, with a waiting period of at least one to two weeks between adjustments to accurately assess the resulting glycemic response. Due to its meal-dependent action, the corresponding dose must be skipped entirely if a meal is missed. For patients with severe renal impairment or hepatic impairment, a conservative starting dose of 0.5 mg is used, and dose increases should occur more gradually. This structured protocol defines the standardized, food-coordinated use of repaglinide.

Research Evidence / Overview of Studies for Aglinox

---

Evidence for use in Chronic Migraine

This section will summarize the structure of the short-term Randomized Controlled Trials (RCTs) and longer open-label studies that explored how symptoms change over time when Aglinox was administered in adults diagnosed with chronic migraine.

Aglinox was studied for chronic migraine, a condition characterized by fluctuating or episodic manifestations of headaches. Research primarily involved short-term randomized trials. These trials focused on outcomes related to physical discomfort, specifically measuring changes in the number of migraine days patients experienced each month. Research reports measurements observed during the study period, including variations in monthly migraine day counts across study groups. The most significant gap is that long-term effects are not fully established, and data for certain groups remain insufficient, particularly for very elderly patients or adolescents.

---

Evidence for use in Type 2 Diabetes

This part will describe the clinical trial research, including long-term Cardiovascular Outcome Trials (CVOTs) and short-term efficacy studies, that measured the outcomes related to systemic or functional imbalance when Aglinox was administered to adults with Type 2 Diabetes.

Aglinox was evaluated in a number of short-to-intermediate-term Phase 3/4 randomized trials, as well as very large, long-term CVOTs. The primary outcomes monitored were changes in blood sugar parameters, such as measuring HbA1c levels, and changes in body weight. Long-term CVOTs explored safety and outcomes monitoring cardiovascular measures, specifically the incidence of major heart-related events over several years.

Findings describe measurements of HbA1c levels reported during the study period. Follow-up durations were limited for the assessment of long-term kidney-related complications. Data for certain groups remain insufficient, specifically for pediatric or adolescent populations, as the results apply only to the populations studied in the major adult trials.

---

What is still uncertain about Aglinox research

Across both indications, long-term effects are not fully established, and there is limited information for long-term outcomes beyond the study durations. For chronic migraine, evidence quality varies across studies, and the heterogeneity makes it difficult to draw broad conclusions. For Type 2 Diabetes, the certainty remains low regarding the long-term impact on all microvascular outcomes related to systemic or functional imbalance.

Common questions about Aglinox (FAQ)

---

Q: How quickly does Aglinox start working after the first dose?

Official information indicates that the active ingredient in Aglinox is rapidly absorbed after being taken. This fast action means the highest concentration of the medicine in the blood is typically reached within one hour (0.5 to 1.4 hours) of administration.

---

Q: How long does the effect of Aglinox last in the body?

The drug's maximum blood glucose-lowering effect is generally observed within three to three and a half hours after taking a dose. The resulting increase in plasma insulin levels remains for a short period, typically between four to six hours.

---

Q: What happens if Aglinox is stopped suddenly, according to official information?

Official warnings state that temporary discontinuation of the medicine may be required during times of physical stress, such as illness or surgery, sometimes requiring the use of insulin. Loss of blood glucose control when discontinuing treatment may cause high blood sugar levels to return to abnormal levels.

---

Q: What are the storage guidelines for Aglinox?

Official labeling describes the requirement to store Aglinox at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The container is required to be kept tightly closed, protected from light and moisture, and stored out of the reach of children.

---

Q: What are the specific warnings about stopping treatment with Aglinox?

Official warnings indicate that the dose is skipped entirely if a meal is missed. Furthermore, during times of stress, such as a fever or infection, temporary discontinuation and a switch to insulin treatment may be required, as outlined in the prescribing information.

---

Q: Is Aglinox intended for short-term or long-term use?

The medicine has been studied in both short-to-intermediate-term clinical trials and very large, long-term studies to assess cardiovascular outcomes. While it may be used short-term during temporary loss of blood glucose control, full effects on fasting blood glucose levels are typically not observed until after approximately one month of therapy.

---

Q: Are generic versions of Aglinox available?

Yes, the active ingredient contained in Aglinox, called repaglinide, is described in regulatory documents as being available in generic versions in various countries and regions.

---

Q: Why does the packaging state that Aglinox should be kept out of light?

Official guidelines describe the need for the tablets to be kept in the original container and protected from light. This measure is necessary to help maintain the quality and chemical stability of the medicine over its shelf life.

---

Q: Is it normal to feel a certain symptom (e.g., mild headache) when starting Aglinox?

Official safety documents classify headache as a Common adverse reaction. This means it is among the side effects that have been frequently reported in studies.

---

Q: Does Aglinox cause drowsiness or affect alertness?

Drowsiness and dizziness are described in patient information as possible symptoms, but they are generally linked to either low blood sugar (hypoglycemia) or high blood sugar (hyperglycemia). Since the medicine works to regulate blood sugar, these effects may be related to the underlying condition or its treatment.

---

Q: Are there different strengths or dosage forms of Aglinox available?

Regulatory documents confirm that the medicine is manufactured as an oral tablet. It is available in three specific strengths: 0.5 mg, 1 mg, and 2 mg.

---

Q: Are there common misunderstandings about the effects of Aglinox that official sources address?

Official regulatory information specifically addresses common points of patient confusion. This includes the statement that the dose is skipped if a meal is missed entirely, and the importance of taking the medication within 15 to 30 minutes before a meal begins.

---

Q: How long has Aglinox been available on the market?

The active substance in Aglinox, repaglinide, has a history dating back to its first regulatory approval. It was first approved by the FDA in the United States in December 1997.

---

Q: Is it true that Aglinox is only effective for a certain subset of patients?

Regulatory documents define the authorized use of Aglinox to adults with Type 2 Diabetes. Official safety and efficacy results are stated to apply only to the populations studied in the major adult trials, excluding groups such as Type 1 Diabetes and pediatric patients.

---

Q: Why is Aglinox considered a controlled substance in the US or other regions?

Official documentation clarifies the regulatory status of the active ingredient, repaglinide. It is classified as not a controlled substance in the US and other regions where this information is published.

Storage and Disposal Requirements for Aglinox

Aglinox (Repaglinide) must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C.

---

Mandatory Conditions and Protection

The tablets must be protected from light and moisture and kept in the original, tightly closed container at all times. It is mandatory to store this medication out of the reach of children.

Disposal

Unused or expired Aglinox must not be disposed of in household trash or poured down the sink or toilet (wastewater). Disposal must strictly follow local regulatory requirements for pharmaceutical waste, such as pharmacy take-back schemes, to ensure proper environmental handling.